Article
Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
Blood - 17 Jun 2021
Byrd John C, Woyach Jennifer A, Furman Richard R, Martin Peter, O'Brien Susan, Brown Jennifer R, Stephens Deborah M, Barrientos Jacqueline C, Devereux Stephen, Hillmen Peter, Pagel John M, Hamdy Ahmed, Izumi Raquel, Patel Priti, Wang Min Hui, Jain Nitin, Wierda William G
Abstract excerpt
Acalabrutinib has demonstrated significant efficacy and safety in relapsed chronic lymphocytic leukemia (CLL). Efficacy and safety of acalabrutinib monotherapy were evaluated in a treatment-naive CLL cohort of a single-arm phase 1/2 trial (ACE-CL-001). Adults were eligible for enrollment if chemotherapy was declined or deemed inappropriate due to comorbidities (N = 99). Patients had a median age of 64 years and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.